[ET Net News Agency, 4 November 2021] Innovent Biologics, Inc. (01801) said the
National Medical Products Administration (NMPA) of China has accepted the supplemental New
Drug Application (sNDA) for sintilimab in combination with chemotherapy (oxaliplatin and
capecitabine) for the first-line treatment of patients with unresectable, locally
advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ)
adenocarcinoma.
Sintilimab, marketed as TYVYT (sintilimab injection) in China, is an innovative PD-1
inhibitor with global quality standards jointly developed by the company and Eli Lilly and
Company. (RC)